Classification
Product TypeIngredient
Product FormExtract
Industry PositionBotanical ingredient for nutraceutical/traditional medicine manufacturing
Market
Noni (mengkudu; Morinda citrifolia) is used in Indonesia’s herbal and health-product sector, creating domestic demand for noni-derived ingredients and extracts. Indonesia’s regulatory framework explicitly covers both Traditional Medicine Industry (IOT) and Natural Extract Industry (IEBA) under BPOM’s Good Manufacturing Practices for traditional medicine (CPOTB), shaping how botanical extracts are produced and quality-assured. Commercial noni-based supplement products in Indonesia highlight typical quality concerns (e.g., microbial and contaminant testing) and market expectations for regulatory registration. For trade classification context, botanical extracts generally map to HS heading 1302 (vegetable saps and extracts), but the exact subheading depends on the product’s specification and intended use.
Market RoleDomestic botanical ingredient producer and consumer market (herbal/traditional medicine and supplements)
Domestic RoleInputs for Indonesian traditional medicine (obat tradisional) and health supplement value chains
Specification
Primary VarietyMorinda citrifolia (noni/mengkudu)
Supply Chain
Risks
Regulatory Compliance HighNon-compliance with BPOM’s CPOTB requirements for the Natural Extract Industry (IEBA) and Traditional Medicine Industry (IOT)—or misalignment between intended use (traditional medicine/supplement ingredient) and the supporting regulatory dossier—can block legal market access and trigger enforcement actions (e.g., inability to supply compliant downstream products).Map intended use early (traditional medicine vs supplement ingredient vs other), align the quality system to CPOTB where applicable (IEBA/IOT), and maintain audit-ready manufacturing and QC documentation.
Food Safety MediumBotanical products in Indonesia’s herbal/supplement supply chain are commonly scrutinized for contaminants (e.g., aflatoxin), heavy metals, and microbial contamination; failures can lead to product rejection and reputational damage.Implement routine lot testing with a competent laboratory (e.g., ISO/IEC 17025-accredited) and maintain clear acceptance specifications and COAs for each batch.
Documentation Gap MediumBuyers and downstream manufacturers may require consistent batch documentation (identity, COA, stability/quality justifications for finished products, and traceability). Gaps can delay onboarding or prevent use in regulated finished products.Standardize documentation packs (identity/marker approach if used, COA, traceability records, and change-control) and align them to downstream BPOM expectations where relevant.
Standards- HACCP (commonly cited by Indonesian manufacturers for finished supplement production)
- GMP/CPOTB-aligned manufacturing controls for traditional medicine and natural extract industries
- ISO/IEC 17025-accredited laboratory testing (referenced by Indonesian manufacturers via KAN-accredited labs)
FAQ
Which Indonesian authority sets GMP expectations relevant to natural extracts used in traditional medicine supply chains?BPOM (Badan Pengawas Obat dan Makanan) requires the Traditional Medicine Industry (IOT) and Natural Extract Industry (IEBA) to implement CPOTB (Good Manufacturing Practices for traditional medicines), which is directly relevant to how botanical extracts are produced and controlled in Indonesia.
Is halal certification relevant for noni-derived ingredients in Indonesia?It can be. BPJPH is the government body mandated under Law No. 33/2014 to organize halal product assurance in Indonesia, and halal certification may be requested or required depending on the downstream product category and sales channel.
What quality hazards are commonly referenced for noni-based supplement products in Indonesia?Indonesian manufacturers commonly reference testing for contaminants such as aflatoxin, heavy metals, and microbial contamination as part of product quality assurance for noni-based supplements.